Back to products

Tirzepatide 15mg/30mg Research Peptide

Name: Tirzepatide 15mg/30mg Research Peptide
SKU: 15839
Price: 100.00 USD
Availability: InStock

Third-Party Tested

≥98% Purity

Fast Shipping

COA Included

For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.

$100.00

Compare

Add to wishlist

Shipping and returns

Authorities in our business will tell in no uncertain terms that Lorem Ipsum is that huge, huge no no to forswear forever. Not so fast, I'd say, there are some redeeming factors in favor of greeking text, as its use is merely the symptom of a worse problem to take into consideration.

Product care

Anyway, you still use Lorem Ipsum and rightly so, as it will always have a place in the web workers toolbox, as things happen, not always the way you like it, not always in the preferred order.

Product details

Made possible by exploring innovative molded plywood techniques, Iskos-Berlin’s Soft Edge Chair blends strong curves with extreme lightness to create a three-dimensionality not usually possible with 2-D plywood.

Description

For Research Purposes Only. Not approved for human consumption.

Tirzepatide Research Peptide

Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide. In Phase 3 SURPASS trials, Tirzepatide achieved up to 22.5% weight loss, surpassing Semaglutide’s results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (Semaglutide) and triple-mechanism (Retatrutide) approaches.

Research Applications

Dual incretin (GIP + GLP-1) receptor research
Advanced metabolic and obesity biology
Comparative single vs. dual agonist efficacy studies
Insulin secretion and glucose metabolism research
Bridge research between Semaglutide and Retatrutide mechanisms

Quality Specifications

Purity: ≥98% (HPLC verified)
Compound: Tirzepatide
Molecular Weight: 4813.5 Da
Form: Lyophilized powder
Storage: -20°C, protect from light
COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: What makes Tirzepatide unique?
A: First dual GIP/GLP-1 agonist (‘twincretin’) to reach Phase 3. Most metabolic peptides target one receptor. Tirzepatide targets two — establishing dual agonism as superior to single-mechanism approaches.

Q: What were the SURPASS trial results?
A: Tirzepatide achieved up to 22.5% weight loss in Phase 3 trials — exceeding Semaglutide’s ~15% and setting the stage for triple agonists like Retatrutide to push further.

Q: How does Tirzepatide fit between Semaglutide and Retatrutide?
A: It is the middle tier: Semaglutide = single agonist (GLP-1 only); Tirzepatide = dual agonist (GLP-1 + GIP); Retatrutide = triple agonist (GLP-1 + GIP + Glucagon). Research often compares all three.

For laboratory research use only. Not for human consumption. Not evaluated by the FDA.

Customer Reviews

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Peptides

$50.00